Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.


Journal

American journal of physiology. Gastrointestinal and liver physiology
ISSN: 1522-1547
Titre abrégé: Am J Physiol Gastrointest Liver Physiol
Pays: United States
ID NLM: 100901227

Informations de publication

Date de publication:
01 04 2019
Historique:
pubmed: 18 1 2019
medline: 25 12 2019
entrez: 18 1 2019
Statut: ppublish

Résumé

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of conditions ranging from simple steatosis (NAFL), over nonalcoholic steatohepatitis (NASH) with or without fibrosis, to cirrhosis with end-stage disease. The hepatic molecular events underlying the development of NAFLD and transition to NASH are poorly understood. The present study aimed to determine hepatic transcriptome dynamics in patients with NAFL or NASH compared with healthy normal-weight and obese individuals. RNA sequencing and quantitative histomorphometry of liver fat, inflammation and fibrosis were performed on liver biopsies obtained from healthy normal-weight ( n = 14) and obese ( n = 12) individuals, NAFL ( n = 15) and NASH ( n = 16) patients. Normal-weight and obese subjects showed normal liver histology and comparable gene expression profiles. Liver transcriptome signatures were largely overlapping in NAFL and NASH patients, however, clearly separated from healthy normal-weight and obese controls. Most marked pathway perturbations identified in both NAFL and NASH were associated with markers of lipid metabolism, immunomodulation, extracellular matrix remodeling, and cell cycle control. Interestingly, NASH patients with positive Sonic hedgehog hepatocyte staining showed distinct transcriptome and histomorphometric changes compared with NAFL. In conclusion, application of immunohistochemical markers of hepatocyte injury may serve as a more objective tool for distinguishing NASH from NAFL, facilitating improved resolution of hepatic molecular changes associated with progression of NAFLD. NEW & NOTEWORTHY Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. NAFLD is associated with the metabolic syndrome and can progress to the more serious form, nonalcoholic steatohepatitis (NASH), and ultimately lead to irreversible liver damage. Using gold standard molecular and histological techniques, this study demonstrates that the currently used diagnostic tools are problematic for differentiating mild NAFLD from NASH and emphasizes the marked need for developing improved histological markers of NAFLD progression.

Identifiants

pubmed: 30653341
doi: 10.1152/ajpgi.00358.2018
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

G462-G472

Auteurs

Malte P Suppli (MP)

Department of Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Kristoffer T G Rigbolt (KTG)

Gubra, Hørsholm , Denmark.

Sanne S Veidal (SS)

Gubra, Hørsholm , Denmark.

Sara Heebøll (S)

Department of Hepatology and Gastroenterology, Aarhus University Hospital , Aarhus , Denmark.

Peter Lykke Eriksen (PL)

Department of Hepatology and Gastroenterology, Aarhus University Hospital , Aarhus , Denmark.

Mia Demant (M)

Department of Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Jonatan I Bagger (JI)

Department of Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Jens Christian Nielsen (JC)

Gubra, Hørsholm , Denmark.

Denise Oró (D)

Gubra, Hørsholm , Denmark.

Sebastian W Thrane (SW)

Gubra, Hørsholm , Denmark.

Asger Lund (A)

Department of Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Charlotte Strandberg (C)

Department of Radiology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Merete J Kønig (MJ)

Department of Radiology, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Tina Vilsbøll (T)

Department of Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen , Denmark.

Niels Vrang (N)

Gubra, Hørsholm , Denmark.

Karen L Thomsen (KL)

Department of Hepatology and Gastroenterology, Aarhus University Hospital , Aarhus , Denmark.

Henning Grønbæk (H)

Department of Hepatology and Gastroenterology, Aarhus University Hospital , Aarhus , Denmark.

Jacob Jelsing (J)

Gubra, Hørsholm , Denmark.

Filip K Knop (FK)

Department of Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen , Denmark.
Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen , Copenhagen , Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH